Introduction:
Polymorphism solid-state characterization CMC work answers one regulatory question: is the crystal form of your drug substance known, stable and consistently controlled? If it is not, bioavailability, shelf life and patent position can all be put at risk, and a regulatory filing can stall.
Crystal form is one of the most underestimated variables in Chemistry, Manufacturing and Controls (CMC). Two batches with the same chemical structure can dissolve at different rates, flow differently in the blender and convert to another form on storage. For that reason, solid-state data now sits at the centre of the drug substance section of regulatory submissions.
ResolveMass Laboratories Inc. is a Canadian analytical CRO/CDMO whose teams work daily with mass spectrometry, biosimilar characterization, PLGA-based drug delivery and nitrosamine testing. In this guide we explain what polymorphism is, which techniques regulators expect, and how to build a defensible solid-state package that supports approval.
For generic drugs, new chemical entities, peptides and complex formulations, solid-state characterization is more than a routine test. It supports process understanding, risk management and regulatory documentation. This article explains why polymorphism matters in CMC, which techniques identify crystal forms, how forms affect manufacturing, and how to build solid-state controls that support regulatory submissions.
Summary:
- Polymorphism is the ability of a compound to exist in multiple crystalline forms with different molecular arrangements.
- Different polymorphs can vary in solubility, dissolution, melting point, stability and bioavailability.
- Solid-state characterization identifies and differentiates polymorphs, hydrates, solvates and amorphous material.
- Polymorphism solid-state characterization CMC work combines XRPD, DSC, TGA, FTIR, Raman, solid-state NMR and microscopy, not a single test.
- Transformations during crystallization, milling, drying, granulation and storage can affect product quality.
- ICH Q6A, ICH Q8(R2), ICH Q11 and FDA polymorph guidance support the scientific evaluation and control of solid-state properties.
- Ritonavir (1998) and rotigotine (2008) show how an unexpected form can force reformulation or withdrawal.
- Early screening, a documented form-selection rationale and a validated XRPD method reduce risk before IND, NDA and ANDA filings.
- A well-designed polymorphism control strategy strengthens CMC documentation, manufacturing consistency and approval readiness.
1: What Is Polymorphism in Pharmaceuticals?
Polymorphism is the ability of a drug substance to exist in two or more crystalline arrangements with the same chemical composition. Each arrangement, called a polymorph, has its own lattice energy and therefore its own physical properties.
Solid forms of an active pharmaceutical ingredient (API) fall into several families:
- Polymorphs: different crystal packing of the same molecule.
- Solvates and hydrates: crystals that incorporate solvent or water in the lattice.
- Salts and co-crystals: multi-component solids; FDA guidance treats co-crystals differently from salts for regulatory classification.
- Amorphous forms: no long-range order, usually more soluble but less physically stable.
Salts and co-crystals sit alongside these forms. Hydrates and solvates are sometimes called pseudopolymorphs because their lattices contain water or solvent, so they need separate consideration during solid-state development.
Only one form is thermodynamically stable at a given temperature and pressure. Metastable forms can dissolve faster, but they may convert to the stable form during manufacturing or storage, which is why the polymorphism solid-state characterization CMC strategy must map the whole landscape.
Why Do Different Polymorphs Have Different Properties?
Polymorphs differ because their molecules pack differently and interact differently, which changes lattice energy and molecular mobility. Important differences include:
- Crystal density and packing efficiency
- Melting point and thermal behaviour
- Solubility and dissolution rate
- Hygroscopicity and moisture uptake
- Mechanical properties, including compressibility
- Physical and chemical stability
- Susceptibility to solid-state transformation
Selecting the right crystal form is therefore an early decision in API development and CMC planning.
2: Why Does Crystal Form Matter for Drug Approval?
Crystal form matters because it changes how the drug behaves in the patient and in the plant, and regulators hold sponsors responsible for both. An uncontrolled form change can alter exposure, shelf life or manufacturability after approval.
| Impact area | What can change with crystal form | Regulatory consequence |
|---|---|---|
| Solubility and dissolution | Metastable forms often dissolve faster | Bioavailability and bioequivalence risk |
| Physical stability | Form conversion during storage | Shelf-life and specification failures |
| Chemical stability | Different reactivity in the solid state | Impurity growth, tighter controls |
| Processability | Flow, compressibility, hygroscopicity | Scale-up and blend-uniformity problems |
| Intellectual property | Distinct forms are separately patentable | Freedom-to-operate and lifecycle strategy |
Two well-known cases show the stakes. In 1998, a new, less soluble form of ritonavir appeared after launch and forced the manufacturer to reformulate the product. In 2008, a rotigotine transdermal patch was recalled after a different crystal form appeared in the product over time. Both cases are widely documented in the pharmaceutical literature.
Solubility, Stability and Bioavailability: What Should You Keep in Mind?
A metastable polymorph often shows higher apparent solubility and faster dissolution than the stable form, but this is compound-specific and must be shown experimentally. It matters most for poorly water-soluble APIs, where dissolution can limit absorption.
A different form does not automatically mean different bioavailability. The impact depends on the API, formulation, dissolution conditions and absorption characteristics. Stability needs the same care, because solid-state transformations can be triggered by:
- Temperature fluctuations
- Exposure to moisture and humidity
- Solvent-mediated crystallization
- Mechanical stress during milling
- Changes in storage conditions
If a metastable form converts during storage and dissolution changes, the product may no longer meet its intended quality profile. Thermodynamically stable forms are often less likely to transform, but chemical stability must be evaluated separately.
3: How Does Polymorphism Affect Pharmaceutical Manufacturing?
Polymorphism can influence every step from API crystallization to final dosage-form production, because temperature, solvent, agitation, drying and mechanical energy can all trigger a solid-state change. Form selection belongs in early process development, not only in final product testing.
Crystallization and API Isolation
Crystallization conditions strongly decide which form appears. Key variables include solvent selection, supersaturation, cooling rate, seeding strategy, agitation, crystallization time and impurities. Uncontrolled cooling or poor seeding can give an undesired polymorph or a mixture of forms, so a systematic crystallization programme is needed to find conditions that give the intended form every time. This is also where scale-up and tech transfer in CMC becomes critical, because a form that is reproducible at lab scale can change when mixing, cooling or drying conditions change.
Milling and Particle Size Reduction
Milling adds mechanical energy, heat and lattice defects. Possible consequences are partial amorphization, polymorphic transformation, changed crystallinity, altered morphology and modified dissolution. XRPD and DSC before and after milling show whether the process changed the solid form.
Drying and Granulation
Drying temperature, humidity and solvent-removal rate influence hydrate and solvate stability. Wet granulation can trigger solvent-mediated transformation or recrystallization, so solid-state data should guide drying endpoints and granulation conditions.
Compression and Storage
Tablet compression applies stress that can change the crystal structure of some APIs, and temperature and humidity swings in storage can promote conversion. Stability studies should confirm that the selected form stays consistent through the proposed shelf life, and packaging interactions are reviewed alongside them, as described in our guide to extractables and leachables in CMC.
4: What Do Regulators Expect from Polymorphism Solid-State Characterization in CMC?
Regulators expect you to identify the forms that exist, show which one you manufacture, and prove that your controls keep it consistent through shelf life. The expectations come from several harmonized and regional documents:
- ICH Q6A: includes a decision tree on polymorphism and sets out when a solid-form specification is needed for the drug substance.
- ICH Q8(R2) and Q11: link critical material attributes and the drug substance control strategy to product quality.
- ICH Q1A(R2): stability studies must be able to detect form changes that affect quality.
- FDA guidance on pharmaceutical solid polymorphism (ANDA): describes how generic sponsors should show the form and its impact on performance.
- FDA guidance on co-crystals: clarifies how co-crystals are classified relative to salts and polymorphs.
In practice, reviewers look for four things: a screen that explored the solid-form landscape, a rationale for the selected form, validated methods that can tell forms apart, and a control strategy tied to specifications. Sponsors should always confirm current requirements with the relevant authority before filing.
5: Which Solid-State Characterization Techniques Are Used in CMC?
No single technique is enough; a defensible package combines orthogonal methods. X-ray powder diffraction (XRPD) is the primary fingerprint for crystal form, and thermal, spectroscopic and sorption data confirm what XRPD shows.
| Technique | What it tells you | Typical CMC use |
|---|---|---|
| XRPD | Crystal lattice fingerprint | Form identification, batch release, stability |
| Single-crystal XRD | Full 3D structure | Absolute structure and hydrate/solvate proof |
| DSC | Melting, transitions, glass transition | Form relationships, purity, amorphous content |
| TGA | Mass loss on heating | Solvate and hydrate confirmation |
| DVS | Moisture uptake and release | Hygroscopicity, hydrate formation risk |
| FTIR / Raman | Molecular environment in the solid | Fast ID, in-process monitoring |
| Solid-state NMR | Local structure, mixtures | Quantifying forms, amorphous characterization |
| Microscopy (hot-stage, SEM) | Habit, particle size, transitions | Morphology and process-related changes |
Because polymorphism solid-state characterization CMC data must stand up to review, each method should be qualified or validated for its intended use, with documented system suitability and controlled reference standards.
6: How Is a Polymorph Screen and Form Selection Done?
A polymorph screen crystallizes the API under many conditions, then characterizes every solid that results to pick the most suitable form. The goal is a documented, science-based choice, usually the thermodynamically stable form unless there is a justified reason to choose otherwise.
- Define the target profile: dose, route, solubility needs and manufacturing process.
- Run the screen: vary solvents, temperature, cooling rate, slurrying and humidity.
- Characterize every solid: XRPD first, then DSC, TGA, DVS and spectroscopy.
- Map form relationships: determine which form is stable and which are metastable.
- Stress and slurry-test: challenge the lead form with heat, humidity, milling and compaction.
- Select and justify the form: record the rationale for the CMC dossier.
- Set controls: validate an identity method and define specifications and stability monitoring.
This sequence is the backbone of any polymorphism solid-state characterization CMC package, and completing it before pivotal batches avoids repeating clinical or stability work.
7: What Are the Most Common Solid-State Pitfalls in CMC?
The most common pitfalls are incomplete screening, non-discriminating methods and ignoring process-induced change. Most are avoidable with early, orthogonal testing.
- Screening too narrowly: a screen with few solvents can miss a more stable form that appears later.
- Relying on XRPD alone: mixtures, low-level forms and amorphous content can be missed without complementary methods.
- Ignoring process effects: milling, drying, granulation and compression can induce form change.
- Weak limits of detection: a method that cannot detect a minor form cannot support a specification.
- Poor sample handling: preferred orientation and moisture exposure can distort XRPD and DVS results.
- Unclear data trail: gaps in raw data, audit trails or reference-standard control undermine credibility with reviewers.
How Does ResolveMass Support Polymorphism Solid-State Characterization in CMC?
ResolveMass Laboratories Inc. supports solid-state work as part of a wider analytical and CMC programme, with science-led study design and documentation written for regulatory review. As a Canadian analytical CRO/CDMO, our teams combine deep experience in mass spectrometry, biosimilar characterization, PLGA-based drug delivery systems and nitrosamine testing with the orthogonal thinking that solid-form questions demand.
What sponsors can expect from us:
- Scientist-led design: study plans matched to your development stage and filing route.
- Orthogonal data: several complementary techniques interpreted together, not isolated results.
- Regulatory-ready reporting: clear methods, traceable data and rationale aligned to ICH and FDA expectations.
- Integrated support: solid-state findings linked to impurity, stability and drug-delivery questions in the same programme.
Conclusion:
Polymorphism solid-state characterization CMC work is not a box to tick at filing; it is how you prove that the drug you tested is the drug you will manufacture and sell. Early screening, orthogonal characterization and validated controls protect bioavailability, stability and patent value, and they give regulators the confidence to approve.
Frequently Asked Questions:
XRPD identifies crystalline forms by analyzing their characteristic diffraction patterns. It helps differentiate polymorphs, detect crystalline phase changes, and evaluate the crystallinity of pharmaceutical materials.
Yes. Different crystal structures can have different lattice energies, resulting in variations in solubility and dissolution rates. These differences may influence drug absorption and bioavailability, particularly for poorly water-soluble APIs.
DSC measures heat-flow changes during thermal events such as melting, crystallization, and solid-state transitions. TGA measures changes in sample weight and is useful for evaluating moisture loss, solvent removal, and thermal decomposition.
Hydrates are crystalline forms containing water molecules within their crystal structures, while solvates contain organic or other solvent molecules. Both can influence API stability, moisture sensitivity, and pharmaceutical manufacturing.
Reference
- Li ZJ, Lu Y, Wang R, Dong X, Chen P, Duan J, Shi M, Wang L, Liu Y. A survey of solid form landscape: Trends in occurrence and distribution of various solid forms and challenges in solid form selection. Journal of Pharmaceutical Sciences. 2025 Jan 1;114(1):586-91.https://www.sciencedirect.com/science/article/pii/S0022354924004957
- Becker A. API co-crystals–Trends in CMC-related aspects of pharmaceutical development beyond solubility. Drug Discovery Today. 2023 May 1;28(5):103527.https://www.sciencedirect.com/science/article/pii/S1359644623000430
- Gruss M. Regulatory aspects for formulation design–with focus on the solid state. Innovative Dosage Forms: Design and Development at Early Stage. 2019 Oct 7:155-207.https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527812172.ch5
- von Raumer M, Hilfiker R. Solid state and polymorphism of the drug substance in the context of quality by design and ICH Guidelines Q8–Q12. Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development. 2018 Dec 10:1-30.https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527697847.ch1
- Kedar AA. Effect Of Different Crystal Forms Of Aceclofenac On Formulation Development (Master’s thesis, Rajiv Gandhi University of Health Sciences (India)).https://search.proquest.com/openview/cf519f8cba59df5d7b9ce7e583e5257d/1?pq-origsite=gscholar&cbl=2026366&diss=y
About the Author
